TAL Education Group (TAL)

Inozyme Pharma Stock Forecast

Stock Price Forecast

The 4 analysts that cover Inozyme Pharma stock have a consensus rating of "Buy" and an average price target of $12.66, which forecasts a 18.98% increase in the stock price over the next year. The lowest target is $10.9 and the highest is $17.2.

Price Target: $12.66 (+18.98%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$10.9	$12.66	$11.54	$17.2
Change	+2.44%	+18.98%	+8.46%	+61.65%

* Price targets were last updated on Jun 27, 2025.

Analyst Ratings

The average analyst rating for Inozyme Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	2	2	2	2	1	1
Buy	1	1	0	0	0	0
Hold	0	0	2	2	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Alice Cai Citigroup	Citigroup	Strong Buy → Hold Downgrades $13 → $12	Strong Buy → Hold	Downgrades	$13 → $12	+8.46%	Jun 27, 2025
Linda Huang Macquarie	Macquarie	Buy → Hold Downgrades $15 → $11	Buy → Hold	Downgrades	$15 → $11	+2.44%	Apr 25, 2025
DS Kim JP Morgan	JP Morgan	Buy → Hold Downgrades $16 → $11	Buy → Hold	Downgrades	$16 → $11	+3.38%	Apr 24, 2025
DS Kim JP Morgan	JP Morgan	Buy Maintains $17 → $16	Buy	Maintains	$17 → $16	+50.38%	Apr 21, 2025
Felix Liu UBS	UBS	Strong Buy Maintains $16 → $17	Strong Buy	Maintains	$16 → $17	+61.65%	Jan 24, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

3.00B

Increased by 33.45%

from 2.25B

Revenue Next Year

3.72B

Increased by 24.01%

from 3.00B

EPS This Year

0.44

Increased by 223.96%

from 0.14

EPS Next Year

0.64

Increased by 43.98%

from 0.44

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028
Period Ending	Feb 28, 2021	Feb 28, 2022	Feb 28, 2023	Feb 29, 2024	Feb 28, 2025	Feb 28, 2026	Feb 28, 2027	Feb 28, 2028
Revenue	4.50B	4.39B	1.02B	1.49B	2.25B	3.00B	3.72B	4.38B
Revenue Growth	37.35%	-2.33%	-76.78%	46.15%	50.98%	33.45%	24.01%	17.62%
EPS	-0.19	-1.76	-0.21	-0.01	0.14	0.44	0.64	0.78
EPS Growth	-	-	-	-	-	223.96%	43.98%	22.22%
Forward PE	-	-	-	-	-	24.03	16.69	13.65
No. Analysts	-	-	-	-	-	21	21	14

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030
High	3.4B	4.4B	5.3B
Avg	3.0B	3.7B	4.4B
Low	2.8B	3.3B	3.8B

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030
High	51.0%	46.1%	41.3%
Avg	33.5%	24.0%	17.6%
Low	22.5%	9.9%	1.7%

EPS Forecast

EPS	2026	2027	2028	2029	2030
High	1.29	1.69	2.12
Avg	0.44	0.64	0.78
Low	0.31	0.44	0.25

EPS Growth

EPS Growth	2026	2027	2028	2029	2030
High	844.8%	281.7%	232.6%
Avg	224.0%	44.0%	22.2%
Low	129.4%	-0.4%	-61.1%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.